Inj, nyvepria
Products billed under this code include Nyvepria.
Payment limit per 0.5 MG, by effective quarter, 2Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Nyvepria.
Payment limit per 0.5 MG, by effective quarter, 2Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Nyvepria | Pfizer Inc | 00069-0324-01 | 12 | $1,695.468 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $141.289 | +$4.378 | 0.5 MG | Inj, nyvepria | v1, posted September 17, 2026 |
| 3Q26 | $136.911 | +$3.60 | 0.5 MG | Inj, nyvepria | v1, posted September 15, 2026 |
| 2Q26 | $133.311 | +$0.257 | 0.5 MG | Inj, nyvepria | v1, posted September 15, 2026 |
| 1Q26 | $133.054 | +$1.896 | 0.5 MG | Inj, nyvepria | v1, posted September 15, 2026 |
| 4Q25 | $131.158 | −$0.881 | 0.5 MG | Inj, nyvepria | v1, posted September 8, 2026 |
| 3Q25 | $132.039 | −$2.213 | 0.5 MG | Inj, nyvepria | v1, posted March 10, 2026 |
| 2Q25 | $134.252 | +$17.242 | 0.5 MG | Inj, nyvepria | v1, posted March 10, 2026 |
| 1Q25 | $117.01 | +$20.462 | 0.5 MG | Inj, nyvepria | v1, posted December 19, 2025 |
| 4Q24 | $96.548 | +$16.953 | 0.5 MG | Inj, nyvepria | v1, posted June 11, 2025 |
| 3Q24 | $79.595 | +$14.089 | 0.5 MG | Inj, nyvepria | v1, posted June 11, 2025 |
| 2Q24 | $65.506 | +$3.129 | 0.5 MG | Inj, nyvepria | v1, posted March 11, 2025 |
| 1Q24 | $62.377 | −$26.603 | 0.5 MG | Inj, nyvepria | v1, posted December 19, 2024 |
| 4Q23 | $88.98 | −$11.495 | 0.5 MG | Inj, nyvepria | v1, posted October 10, 2024 |
| 3Q23 | $100.475 | −$22.188 | 0.5 MG | Inj, nyvepria | v1, posted June 5, 2024 |
| 2Q23 | $122.663 | −$21.20 | 0.5 MG | Inj, nyvepria | v1, posted February 23, 2024 |
| 1Q23 | $143.863 | −$27.515 | 0.5 MG | Inj, nyvepria | v1, posted December 6, 2023 |
| 4Q22 | $171.378 | −$46.307 | 0.5 MG | Inj, nyvepria | v1, posted June 22, 2023 |
| 3Q22 | $217.685 | −$25.36 | 0.5 MG | Inj, nyvepria | v1, posted June 9, 2023 |
| 2Q22 | $243.045 | −$26.096 | 0.5 MG | Inj, nyvepria | v1, posted December 14, 2022 |
| 1Q22 | $269.141 | −$15.551 | 0.5 MG | Inj, nyvepria | v1, posted June 8, 2022 |
| 4Q21 | $284.692 | −$29.522 | 0.5 MG | Inj, nyvepria | v1, posted June 2, 2022 |
| 3Q21 | $314.214 | −$22.682 | 0.5 MG | Inj, nyvepria | v1, posted June 2, 2022 |
| 2Q21 | $336.896 | – | 0.5 MG | Inj, nyvepria | v1, posted March 1, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.